

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Musculoskeletal disease	TNF-like weak inducer of apoptosis (TWEAK)	<p><i>In vitro</i> and mouse studies suggest inhibiting TWEAK could promote muscle regeneration after injury. In <i>Tweak</i>^{-/-} mice, the number of self-renewing satellite cells in muscle after injury was higher than that in wild-type controls. In primary satellite cells from the mice, Tweak decreased the number of self-renewing satellite cells compared with no treatment. Next steps could include testing the effects of TWEAK inhibition on muscle regeneration.</p> <p>Biogen Idec Inc. has BIIB023, a mAb against TWEAK, in Phase II trials to treat lupus nephritis.</p> <p>SciBX 6(46); doi:10.1038/scibx.2013.1326 Published online Dec. 5, 2013</p>	Patent and licensing status unavailable	<p>Ogura, Y. <i>et al. J. Biol. Chem.</i>; published online Oct. 22, 2013; doi:10.1074/jbc.M113.517300</p> <p>Contact: Ashok Kumar, University of Louisville School of Medicine, Louisville, Ky. e-mail: ashok.kumar@louisville.edu</p>